Oral Duvelisib Potential New Option for Indolent Non-Hodgkin Lymphoma

The DYNAMO study demonstrated that the oral PI3K gamma inhibitor duvelisib produced an overall response rate in patients with heavily pretreated indolent non-Hodgkin lymphoma.

Source: CancerNetwork - February 26, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news